PDCD1 and melanoma: As a notable example, the Danish Medicines Council specifically did not recommend anti-PD-1 (pembrolizumab) for stage IIB/C melanoma given the lack of known OS benefit and lack of documented positive correlation between RFS and OS,21 and connected the reimbursement of pembrolizumab for resected stage III melanoma to a re-evaluation in 2027,22 with a similar re-evaluation to be conducted in the Netherlands23 and Sweden.24